Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial

Baunwall, Simon Mark Dahl; Andreasen, Sara Ellegaard; Hansen, Mette; Kelsen, Jens; Høyer, Katrine Lundby; Rågård, Nina; Eriksen, Lotte Lindgreen; Støy, Sidsel; Rubak, Tone; Damsgaard, Else Marie; Mikkelsen, Susan; Erikstrup, Christian; Dahlerup, Jens Frederik; Hvas, Christian Lodberg

doi:10.1016/s2468-1253(22)00276-x

Cited by 75 publications

(59 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a subgroup analysis dividing the population into the number CDI recurrences, the increased treatment efficacy in the FMT capsule treated patients remained in the subgroups with first CDI to 1st recurrence and 2nd recurrence, but we found no difference in efficacy in patients with ≥3rd recurrences ( Supplementary Material, Table S1 ) compared with FMT enema and RBT. Albeit the large confidence intervals suggest that the sample size is too small, it might indicate that patients with ≥3rd recurrences are difficult to treat, even with FMT capsules and that FMT must be given at an early stage [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study

Svensson

Cold

Ribberholt

et al. 2022

Cells

View full text Add to dashboard Cite

The most effective treatment for recurrent Clostridioides difficile infection (CDI) is faecal microbiota transplantation (FMT); however, the optimal route of administration is thus far unknown. This retrospective cohort study of 343 patients sought to evaluate the efficacy of treatment with FMT capsules, FMT enema, and rectal bacteriotherapy (RBT) during a five-year period. The primary endpoint was clinical resolution from CDI after eight weeks, and secondary endpoints were time to recurrence and death during the follow-up period. The proportion of patients with clinical resolution was 79.9% in the FMT capsule group, 53.3% in the FMT enema group, and 61.8% in the RBT group, corresponding to an adjusted odds ratio of 3.79 (CI: 1.82 to 8.26) in the FMT capsule group compared with FMT enema, and 2.92 (CI: 1.49 to 6.03) compared with RBT. The hazards ratio for recurrence within the first 12 months of follow-up was 0.24 (CI: 0.06 to 0.89) in the FMT capsule group compared with FMT enema, and 0.26 (CI: 0.08 to 0.91) compared with RBT. There was no difference in mortality. In conclusion, FMT capsules were more effective than both FMT enema and RBT as treatment of recurrent CDI and reduced the risk of further recurrences.

show abstract

Section: Discussionmentioning

confidence: 99%

The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study

Svensson

Cold

Ribberholt

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…This article is linked to Hocking et al paper. To view this article, visit https://doi.org/10.1111/apt.17309 Ayushi Chauhan 1 Mayur Garg 1,2…”

Section: N K Ed Co Ntentmentioning

confidence: 99%

“…There is little doubt about the clinical efficacy of FMT for recurrent or refractory C. difficile infection, and emerging data suggest superiority over vancomycin in first C. difficile infection 2 . Furthermore, the cost‐effectiveness of FMT over antibiotics, based upon decision‐analytic modelling, has been previously demonstrated across various health systems 3,4 …”

mentioning

confidence: 99%

Editorial: faecal microbiota transplantation for recurrent C. difficile infections—getting the support that is needed

Chauhan

Garg

2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In people with a first or second Clostridioides difficile infection who had received treatment with vancomycin, faecal microbiota transplantation (FMT) resulted in a higher rate of resolution of diarrhoea compared with placebo 1…”

mentioning

confidence: 99%

Early use of faecal microbiota transplantation forC. difficileinfection

2023

DTB

View full text Add to dashboard Cite

show abstract

Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial

Cited by 75 publications

References 24 publications

The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study

The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study

Editorial: faecal microbiota transplantation for recurrent C. difficile infections—getting the support that is needed

Early use of faecal microbiota transplantation forC. difficileinfection

Contact Info

Product

Resources

About